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Summary
Background.  —  Infective  endocarditis  (IE)  is  associated  with  signiﬁcant  morbidity  and  mortality.
Red cell  distribution  width  (RDW)  is  a  recently  recognized  biomarker  of  adverse  outcome  in  a
number of  acute  and  chronic  conditions.
Aim.  —  To  investigate  the  relationship  between  RDW  and  1-year  survival  in  patients  with  IE.
Methods. —  Clinical  records  from  two  tertiary  centres  were  used  to  analyze  data  from  patients
with deﬁnite  IE.  Clinical,  echocardiographic  and  biochemical  variables  were  evaluated  along
with RDW.  One-year  survival  status  after  index  hospitalization  was  identiﬁed  for  each  patient.
Results.  —  One  hundred  consecutive  patients  (mean  age  47.8  ±  16.7  years;  61%  men)  with  deﬁ-
nite IE  were  enrolled.  According  to  receiver  operating  characteristic  curve  analysis,  the  optimal
RDW cut-off  value  for  predicting  mortality  was  15.3%  (area  under  the  curve  0.70;  P  =  0.001).
Forty-one  patients  (41%)  died  within  1  year;  of  these,  88%  had  RDW  results  >  15.3%.  Univariate
Cox proportional-hazards  analysis  showed  that  RDW  >  15.3%,  heart  failure,  renal  failure,  car-
diac abscess,  severe  valvular  regurgitation  and  presence  of  dehiscence  were  associated  with
increased  mortality.  Multivariable  Cox  proportional-hazards  analysis  revealed  that  renal  failure
(hazard ratio  [HR]  3.21,  95%  conﬁdence  interval  [CI]  1.35—7.59;  P  =  0.008),  heart  failure  (HR
2.77, 95%  CI  1.1—6.97;  P  =  0.03)  and  RDW  >  15.3%  (HR  3.07,  95%  CI  1.06—8.86;  P  =  0.03)  were
independent  predictors  of  mortality  in  patients  with  IE.
Abbreviations: IE, infective endocarditis; RDW, red cell distribution width; ROC, receiver operating characteristic.
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Conclusion.  —  According  to  our  results,  mortality  is  high  in  patients  with  IE.  RDW  is  a  promising
biomarker  for  predicting  1-year  survival  rates  in  these  patients.
© 2014  Published  by  Elsevier  Masson  SAS.  CCLcopyrightThis  is  an  open  access  article  under  the
CC BY-NC-SA  license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Résumé
Justiﬁcation.  —  L’endocardite  infectieuse  est  associée  à  une  augmentation  de  la  morbi-
mortalité signiﬁcative.  La  distribution  érythrocytaire  est  un  biomarqueur  de  description  récente
prédisant  les  complications  dans  différentes  situations  aiguës  et  chroniques.
Objectif.  — Évaluer  la  relation  entre  ce  biomarqueur  et  la  survie  à  un  an  chez  des  patients
hospitalisés  pour  endocardite  infectieuse.
Méthode.  —  Les  dossiers  cliniques  de  deux  centres  tertiaires  ont  été  utilisés  pour  analyser  les
informations  à  partir  des  dossiers  de  patients  ayant  une  endocardite  infectieuse  certaine.  Les
données cliniques,  échocardiographiques  et  biochimiques  ont  été  évaluées  parallèlement  à
l’évaluation  de  ce  biomarqueur.  La  survie  à  un  an  après  l’hospitalisation  initiale  a  été  identiﬁée
pour chaque  patient.
Résultats.  —  Cent  patients  consécutifs  (âge  moyen  47,8  ±  16,7  ans  ;  61  %  d’hommes)  ayant  une
endocardite  infectieuse  certaine  ont  été  inclus.  En  utilisant  l’analyse  basée  sur  les  surfaces
sous la  courbe  ROC,  la  valeur  seuil  optimale  pour  ce  biomarqueur  prédisant  la  mortalité  était
de 15,3  %  (surface  sous  la  0,70  ;  p  =  0,001).  Quarante  et  un  patients  (41  %)  sont  décédés  dans
l’année. Parmi  eux  88  %  avaient  un  taux  de  biomarqueur  >  15,3  %.  L’analyse  univariée  selon
le modèle  proportionnel  de  Cox  a  montré  qu’une  valeur  >  15,3,  la  présence  d’une  insufﬁsance
cardiaque,  d’une  insufﬁsance  rénale,  d’un  abcès  cardiaque,  une  régurgitation  valvulaire  signiﬁ-
cative et  la  présence  d’une  déhiscence  valvulaire  étaient  associées  à  une  surmortalité.  L’analyse
multivariée selon  le  modèle  de  Cox  a  indiqué  que  l’insufﬁsance  rénale  (hazard  ratio  [HR]  3,21,
IC 95  %  1,35—7,59  ;  p  =  0,008),  l’insufﬁsance  cardiaque  (HR  2,77,  IC  95  %  1,1—6,97  ;  p  =  0,03)  et
le biomarqueur  de  distribution  érythrocytaire  >  15,3  %  (HR  3,07  ;  IC  95  %  1,06—8,86  ;  p  =  0,03).
Conclusion.  — Nos  résultats  suggèrent  qu’il  existe  une  surmortalité  chez  les  patients  ayant  une
endocardite  infectieuse.  Ce  biomarqueur  paraît  intéressant  pour  prédire  la  survie  à  un  an  chez
les patients  hospitalisés  pour  endocardite  infectieuse  conﬁrmée.
© 2014  Publié  par  Elsevier  Masson  SAS.  CCLcopyrightThis  is  an  open  access  article  under  the
CC BY-NC-SA  license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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wackground
nfective  endocarditis  (IE)  is  an  endovascular  infection  of
he  heart  that  usually  affects  valvular  structures  and,  with
ncreasing  frequency,  implants  within  the  heart,  such  as
rosthetic  valves  or  pacemaker  electrodes.  There  have  been
igniﬁcant  improvements  in  the  treatment  of  most  cardio-
ascular  diseases  in  recent  decades;  however,  prognosis  still
emains  poor  in  IE.  The  current  in-hospital  mortality  rate  is
round  20%,  while  long-term  mortality  can  be  as  high  as  40%
1—3].
Identifying  patients  at  increased  risk  of  adverse  outcomes
s  challenging  due  to  the  broad  spectrum  of  the  cardiac
athology  and  infecting  organisms.  Right-sided  native-valve
E  usually  has  a  benign  course,  with  even  a  short-term
ntibiotic  regimen  being  sufﬁcient,  while  prosthetic  IE  or
evice-related  IE  can  be  more  severe,  requiring  different
anagement  strategies  [4].  The  causative  organism  can
iffer  depending  on  the  history  of  surgery,  drug  abuse,
ealthcare  contact,  invasive  procedures,  immunosuppres-
ion  and  even  geographical  differences  [3].  Although  some
linical  predictors  have  been  identiﬁed  to  estimate  poor
utcome,  the  course  of  the  disease  can  still  differ  in  each
ndividual  [5].  A  biomarker  that  predicts  outcome  would  be
C
E
[elpful  in  clinical  practice  to  identify  high-risk  patients  that
eed  more  aggressive  treatment.
Red  cell  distribution  width  (RDW)  —  a  measure  of  red
lood  cell  size  heterogeneity  —  has  been  used  traditionally
n  the  differential  diagnosis  of  anaemia,  as  it  can  increase
n  cases  of  haemolysis,  blood  transfusion  or  ineffective  ery-
hropoiesis.  Recent  studies  have  shown  that  elevated  RDW  is
ssociated  with  adverse  outcome  in  various  clinical  settings,
ncluding  thromboembolic  events,  cardiovascular  diseases
nd  respiratory  diseases  [6—9]. The  prognostic  implications
f  RDW  in  IE  have  not  been  studied.  In  the  present  study,
e  aimed  to  investigate  the  relationship  between  RDW  and
-year  survival  in  patients  with  IE.
ethods
tudy patients
etween  January  2008  and  January  2011,  patients  diagnosed
ith  deﬁnite  IE  (according  to  the  modiﬁed  Duke  criteria)  at
umhuriyet  University  Faculty  of  Medicine  and  Yuksek  Ihtisas
ducation  and  Research  Hospitals  were  enrolled  in  this  study
10]. Patients  with  chronic  liver  disease  and  those  with  a
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FNew  prognostic  marker  for  infective  endocarditis  
history  of  haematological  disease  other  than  anaemia  (such
as  leukaemia,  myeloproliferative  diseases  or  bone  marrow
inﬁltration)  were  excluded.  The  prospective  data  of  100
consecutive  IE  patients  were  analysed  retrospectively.  In
addition  to  RDW  levels  on  admission,  clinical,  echocardio-
graphic  and  laboratory  ﬁndings  were  recorded  for  each  sub-
ject.  Predisposing  heart  diseases,  including  prosthetic  valve,
pre-existing  valvular  disease  (rheumatic  heart  disease  and
degenerative  valves),  congenital  heart  disease,  implantable
cardiac  device,  nosocomial  infection,  previous  history  of  IE,
malignancy  and  immunosuppression  were  assessed.
Complications  during  hospitalization,  such  as  heart  fail-
ure,  renal  failure,  abscess  formation,  embolic  events
(excluding  cerebral),  cerebrovascular  events  and  surgi-
cal  treatment  for  IE,  were  recorded.  Duration  of  hospital
stay  and  in-hospital  mortality  were  noted.  Cerebrovascular
events  were  deﬁned  in  case  of  the  following  presentations:
intracranial  haemorrhage;  ischaemic  stroke;  or  transient
ischaemic  attacks.  Renal  failure  was  deﬁned  by  serum  creat-
inine  concentration  >  2  mg/dL  during  hospital  stay.  Anaemia
was  deﬁned  according  to  the  World  Health  Organiza-
tion  criteria  (haemoglobin  <  13  g/dL  in  men  and  <  12  g/dL  in
women).  The  study  endpoint  was  the  incidence  of  all-cause
death  within  1  year  after  index  hospitalization.  Clinical
event  data  were  collected  during  the  follow-up  period
for  all  patients  by  reviewing  medical  ﬁles  and  by  tele-
phone  contact.  The  study  was  performed  in  accordance  with
the  Declaration  of  Helsinki  for  human  research  and  was
approved  by  the  local  ethics  committee.
Laboratory
Blood  samples  were  obtained  after  admission,  following
overnight  fasting.  Baseline  RDW,  haemoglobin,  haematocrit,
platelet  count  and  white  blood  cell  count  values  were  mea-
sured  using  an  automated  haematology  analyser.  C-reactive
protein,  glucose  and  creatinine  concentrations  were  mea-
sured  accordingly.  At  least  three  sets  of  blood  samples  for
cultures  were  obtained  from  each  patient  immediately  after
hospital  admission.  Any  other  available  ﬂuid,  tissue  (valves,
vegetations  or  intracardiac  abscesses  removed  at  surgery)
or  foreign  body  samples  (pacemaker  leads,  catheters)  were
used  to  isolate  microorganisms.
Echocardiography
All  patients  underwent  two-dimensional  transthoracic
echocardiography  within  24  hours  of  admission.  Echocar-
diographic  examinations  were  performed  with  the  Vivid  7
system  (GE  Healthcare,  Wauwatosa,  WI,  USA)  in  two  par-
ticipating  centres.  Transoesophageal  echocardiography  was
performed  when  image  quality  with  transthoracic  echocar-
diography  was  insufﬁcient  for  an  accurate  diagnosis  or
in  cases  of  high  clinical  suspicion  of  IE,  prosthetic  valve
involvement  and  suspicion  of  complications.  Vegetation,
abscess  formation  and  valvular  destruction,  such  as  per-
foration  of  leaﬂet  and  chordal  rupture,  were  evaluated.
Vegetation  size  was  measured  by  using  different  echocar-
diographic  windows;  the  maximal  length  was  obtained.
Existence  of  rocking  motion  of  the  prosthetic  valve  with  an
excursion  of  >  15◦ in  at  least  one  direction  gave  the  diag-
nosis  of  dehiscence.  Left  ventricular  ejection  fraction  was
s
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alculated  by  the  modiﬁed  Simpson’s  method.  Severe  valvu-
ar  regurgitation  was  identiﬁed  according  to  guideline
ecommendations  [11].  Pulmonary  artery  systolic  pressure
as  estimated  by  continuous  wave  Doppler  imaging  of  the
ricuspid  regurgitation  using  the  Bernoulli  equation  [12].
tatistics
ontinuous  variables  were  expressed  as  mean  ±  standard
eviation  or  median  with  interquartile  range;  categorical
ariables  were  expressed  as  number  and  percentage.  A
hi-square  test  or  Fisher’s  exact  test  was  performed  to  com-
are  categorical  variables.  The  normality  of  distributions  of
ariables  was  assessed  using  the  Kolmogorov-Smirnov  test.
tudent’s  t-test  was  used  for  normally  distributed  contin-
ous  variables;  the  Mann-Whitney  U  test  was  used  when
he  distribution  was  skewed.  The  discrimination  of  RDW
or  1-year  survival  was  evaluated  using  the  area  under  the
eceiver  operating  characteristic  (ROC)  curve.  The  optimal
ut-off  point  for  ROC  curves  was  determined  for  maximizing
he  sensitivity  and  speciﬁcity  of  the  RDW  values.  Patients
ith  IE  were  categorized  into  two  groups  on  the  basis  of
he  cut-off  value.  Kaplan-Meier  cumulative  survival  curves
ere  used  to  display  survival  in  two  patient  subgroups  and
og-rank  values  were  calculated  to  assess  the  statistical
igniﬁcance.  Univariate  Cox  proportional-hazards  analyses
ere  used  to  evaluate  the  relationship  between  variables
nd  overall  mortality.  Variables  that  had  a  P value  <  0.1  in
he  univariate  analysis  were  used  in  a  multivariable  Cox
roportional-hazards  model  to  determine  the  independent
rognostic  factors  of  mortality.  The  results  of  the  regression
nalysis  are  presented  as  hazard  ratios  and  95%  conﬁdence
ntervals.  All  statistical  analyses  were  performed  using  SPSS
oftware  version  17.0  (SPSS  Inc.,  Chicago,  IL,  USA).  A  P value
f  0.05  was  considered  statistically  signiﬁcant.
esults
ne  hundred  patients,  who  met  the  inclusion  criteria,  with
en  comprising  61%  of  the  cohort,  were  enrolled  in  our
tudy.  The  mean  age  was  47.8  ±  16.7  years.  The  mean  dura-
ion  of  hospital  stay  was  34.95  ±  19.4  days.  Staphylococcus
pecies  were  the  most  common  microorganisms.  Prosthetic
alves  were  the  prominent  predisposing  factor  in  the  study
ohort.  There  were  45  cases  of  prosthetic  valve  IE,  36  cases
f  native-valve  IE,  10  cases  of  congenital  heart  disease-
elated  IE  and  nine  cases  of  device-related  IE.  Twenty-six
atients  died  during  the  index  hospitalization.  Forty-one
atients  (41%)  died  within  1  year.  Table  1  shows  the  dif-
erences  between  survivors  and  non-survivors  regarding
emographic,  clinical  and  echocardiographic  properties.
enal  failure,  heart  failure,  cardiac  abscess  and  severe
alvular  regurgitation  were  signiﬁcantly  more  common
mong  non-survivors,  whereas  having  surgery  due  to  IE  was
ssociated  with  lower  mortality.
RDW  was  signiﬁcantly  increased  in  fatal  cases  (P  =  0.01).
ig.  1  shows  median  RDW  values  in  survivors  and  non-
urvivors.  According  to  ROC  curve  analysis,  the  optimal
ut-off  value  of  RDW  results  on  admission  for  predicting
-year  mortality  was  >  15.3%,  with  88%  sensitivity  and  53%
peciﬁcity  (area  under  the  curve  0.70,  95%  CI  0.59—0.80;
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Table  1  Baseline  characteristics  and  outcomes  of  the  study  patients.
All patients
(n = 100)
Mortality P
Alive
(n = 59)
Died
(n = 41)
Demographics and predisposing conditions
Female sex 39 (39) 26 (44) 13 (32) 0.21
Age  (years) 47.83 ± 16.76 45.69 ± 16.07 50.09 ± 17.46 0.12
Prosthetic valve 45 (45) 24 (41) 21 (51) 0.29
Pre-existing valvular disease 27 (27) 12 (20) 15 (37) 0.07
Congenital cardiac disease 10 (10) 8 (14) 2 (5) 0.19
Cardiac device 9 (9) 4 (7) 5 (12) 0.48
Nosocomial infection 12 (12) 5 (9) 7 (17) 0.22
Previous IE 10 (10) 5 (9) 5 (12) 0.73
Haemodialysis 3 (3) 2 (3) 1 (2) 1
Othera 2 (2) 2 (3) 0 (0) 0.51
Affected valve
Aortic 39 (39) 21 (36) 18 (44) 0.4
Mitral  38 (38) 25 (42) 13 (32) 0.28
Tricuspid 9 (9) 5 (9) 4 (10) 1
Multiple 9 (9) 5 (9) 4 (10) 1
Echocardiography
Cardiac abscess 7 (7) 1 (2) 6 (15) 0.01
Severe  valvular regurgitation 30 (30) 12 (20) 18 (44) 0.01
Vegetation ≥ 10 mm 61 (61) 34 (58) 27 (66) 0.40
Valvular destructionb 7 (7) 4 (7) 3 (7) 1
Dehiscence 7 (7) 2 (3) 5 (12) 0.11
Pulmonary artery pressure (mmHg) 42 (35—50) 42 (35—48) 44 (37.5—56) 0.22
Left  ventricular ejection fraction (%) 58 (50—60) 60 (55—60) 55 (45—60) 0.13
Laboratory variables on admission
Red cell distribution width (%) 16.35 (14.4—18.65) 15.3 (14.2—17.9) 17.1 (15.75—19.1) 0.01
Haemoglobin (g/dL) 10.87 ± 2.21 11.18 ± 2.13 10.43 ± 2.27 0.09
C-reactive protein (mg/dL) 21.2 (7.15—76.95) 23.1 (7.3—69.6) 18.3 (6.04—84.3) 0.96
Creatinine (mg/dL) 0.92 (0.73—1.4) 0.87 (0.7—1.1) 1.3 (0.8—1.74) 0.004
Glucose (mg/dL) 98 (89—119.7) 98 (89.5—112.5) 101 (88—120) 0.85
White  blood cell count (×103/L) 10 (7.5—14.45) 9.9 (7.4—13) 10.1 (7.65—15.7) 0.32
Platelet count (×103/L) 260.5 (172—329.2) 273 (207—379) 251 (147.5—307) 0.08
Microorganism
Staphylococcus aureus 19 (19) 10 (17) 9 (22) 0.53
Coagulase-negative Staphylococcus 15 (15) 9 (15) 6 (15) 0.93
Streptococcus species 15 (15) 12 (20) 3 (7) 0.07
Brucella species 9 (9) 7 (12) 2 (5) 0.11
Enterococcus species 7 (7) 2 (3) 5 (12) 0.3
Gram-negative Bacilli 1 (1) 1 (2) 0 (0) 1
Fungi  1 (1) 0 (0) 1 (2) 0.41
Culture negative 33 (33) 18 (31) 15 (37) 0.52
In-hospital outcome
Anaemia 68 (68) 39 (66) 29 (71) 0.65
Heart  failure 20 (20) 3 (5) 17 (41) 0.0001
Renal  failure 42 (42) 15 (25) 27 (66) 0.0001
Cerebrovascular events 15 (15) 8 (14) 7 (17) 0.62
Embolic events (excluding cerebral) 10 (10) 9 (15) 1 (2) 0.04
Surgery  for IE 18 (18) 16 (27) 2 (5) 0.004
Spleen  abscess 3 (3) 3 (5) 0 (0) 0.26
Brain  abscess 3 (3) 3 (5) 0 (0) 0.26
Data are number (%), mean ± standard deviation or median (interquartile range). IE: infective endocarditis.
a Cancer, immunosuppression.
b Leaﬂet perforation, chordal rupture.
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Table  2  Comparison  of  the  characteristics  and  outcomes  of  the  patients  according  to  their  red  cell  distribution  width
values.
All  patients
(n =  100)
RDW P
≤  15.3%
(n  =  36)
> 15.3%
(n  =  64)
Demographics,  predisposing  conditions  and  type  of  involvement
Female  sex  39  (39)  15  (42)  24  (37)  0.68
Age  (years)  47.83  ±  16.76  48.67  ±  17.05  47.36  ±  16.72  0.71
Prosthetic  valve  45  (45)  11  (31)  34  (53)  0.02
Pre-existing  valvular  disease 27  (27) 9 (25)  18  (28)  0.73
Congenital  cardiac  disease 10  (10) 6 (17) 4  (6)  0.16
Cardiac  device 9  (9) 4  (11) 5  (8) 0.71
Nosocomial  infection  12  (12)  2  (6)  10  (16)  0.2
Previous  IE  10  (10)  2  (6)  8  (13)  0.32
Haemodialysis  3  (3)  0  (0)  3  (5)  0.55
Othera 2  (2)  1  (3)  1  (2)  1
Echocardiography
Cardiac  abscess  7  (7)  1  (3)  6  (9)  0.41
Severe  valvular  regurgitation  30  (30)  5  (14)  25  (39)  0.008
Vegetation  ≥  10  mm  61  (61)  21  (58)  40  (63)  0.68
Valvular  destructionb 7  (7)  3  (8)  4  (6)  0.7
Dehiscence  7  (7)  1  (3)  6  (9)  0.41
Pulmonary  artery  pressure  (mmHg)  42  (35—50)  33  (40—45.75)  45  (40—53.75)  0.01
Left  ventricular  ejection  fraction  (%)  58  (50—60)  60  (55.75—60)  58  (45—60.75)  0.05
Laboratory  variables  on  admission
Haemoglobin  (g/dL)  10.87  ±  2.21  12.04  ±  2.2  10.21  ±  1.94  0.0001
C-reactive  protein  (mg/dL)  21.2  (7.15—76.95)  11.6  (3.52—42.65)  29.65  (9.08—85.65)  0.03
Creatinine  (mg/dL)  0.92  (0.73—1.4)  0.85  (0.7—1.09)  1.03  (0.76—1.68)  0.01
Glucose  (mg/dL)  98  (89—119.7)  95.5  (87.7—109.2)  99.5  (90—126.2)  0.14
White  blood  cell  count  (×103/L)  10  (7.5—14.45)  9.28  (7.54—12.11)  10.35  (7.5—15.37)  0.21
Platelet  count  (×103/L)  260.5  (172—329.2)  266.5  (201.7—374.7)  256.5  (163.7—326.7)  0.46
Microorganism
Staphylococcus  aureus 19  (19) 3 (8) 16  (25)  0.04
Coagulase-negative  Staphylococcus  15  (15)  6  (17)  9  (14)  0.72
Streptococcus  species  15  (14)  9  (25)  6  (9)  0.03
Enterococcus  species  7  (7)  1  (3)  6  (9)  0.41
Brucella  species  9  (9)  4  (11)  5  (8)  0.71
Gram-negative  Bacilli  1  (1)  1  (3)  0  (0)  0.36
Fungus  1  (1)  0  (0)  1  (2)  1
Culture  negative  33  (33)  12  (33)  21  (33)  0.95
In-hospital  outcome
Anaemia  68  (68)  25  (42)  53  (83)  0.0001
Heart  failure  20  (20)  1  (3)  19  (30)  0.001
Renal  failure  42  (42)  4  (11)  38  (59)  0.0001
Cerebrovascular  events 15  (15)  2  (6)  13  (20)  0.04
Embolic  events  (excluding  cerebral)  10  (10)  4  (11)  6  (9)  0.74
Surgery  for  IE 18  (18)  10  (28)  8  (13)  0.05
Spleen  abscess 3  (3) 0  (0)  3  (5)  0.55
Brain  abscess  3  (3)  1  (3)  2  (3)  1
Mortality
In-hospital  mortality  26  (26)  1  (3)  25  (39)  0.0001
Overall  mortality  within  1  year  41  (41)  5  (14)  36  (56)  0.0001
Data are number (%), mean ± standard deviation or median (interquartile range). IE: infective endocarditis; RDW: red cell distribution
width.
a Malignancy, immunosuppression.
b Leaﬂet perforation, chordal rupture.
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Rigure 1. Comparison of median red cell distribution width (RDW)
alues in survivors and non-survivors.
 =  0.001).  To  evaluate  associations  between  RDW  and
linical  outcome,  patients  were  divided  into  two  groups
ccording  to  this  RDW  cut-off  value  (≤  15.3%  vs.  >  15.3%).
he  properties  of  these  subgroups  were  compared,  as  shown
n  Table  2.  In-hospital  complications  such  as  heart  failure,
enal  failure,  cerebrovascular  events  and  severe  valvular
egurgitation  were  more  common  in  patients  with  increased
DW.  Systolic  pulmonary  artery  pressures  were  elevated  in
his  group  compared  with  in  the  lower  RDW  group.  Also,
-reactive  protein  concentrations  were  higher  and  Staphy-
ococcus  aureus  infection  was  more  common  in  patients  with
ncreased  RDW.
According  to  Kaplan-Meier  survival  analysis,  there  was
 signiﬁcant  reduction  in  survival  rates  within  1  year  in
atients  with  increased  RDW  compared  with  in  the  lower
DW  group  (P  =  0.0001).  Fig.  2  displays  survival  curves  in
hese  patient  subgroups,  derived  from  Kaplan-Meier  sur-
ival  analysis.  Results  of  the  univariate  and  multivariable
ox  proportional-hazards  analyses  for  mortality  are  listed
igure 2. Kaplan-Meier survival curves in patients with lower and
igher red cell distribution width (RDW) values. Cum: cumulative.
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n  Table  3.  RDW  >  15.3%,  heart  failure,  renal  failure,  car-
iac  abscess,  severe  valvular  regurgitation  and  presence  of
ehiscence  were  associated  with  increased  mortality  in  the
nivariate  Cox  proportional-hazards  analysis.  In  the  mul-
ivariable  Cox  proportional-hazards  analysis,  RDW  > 15.3%,
enal  failure  and  heart  failure  remained  independent  pre-
ictors  of  mortality  in  IE.
iscussion
n  our  study  cohort,  41  (41%)  patients  died  during  the
ollow-up  period  of  1  year;  among  the  fatal  cases,  26  (26%)
atients  died  during  hospital  stay.  IE  related  complications,
n-hospital  mortality  rate  and  overall  mortality  rate  were
igher  compared  with  results  published  previously  [1—3].
he  participating  institutions  were  both  tertiary  care  cen-
res  and  the  patient  group  may  have  had  more  co-morbid
onditions  than  the  general  population,  as  more  severe  or
omplicated  cases  may  have  been  referred  from  other  insti-
utions.  The  mean  age  of  the  study  subjects  was  lower  and
rosthetic  valve  was  more  common  compared  with  European
ata,  probably  due  to  higher  prevalence  of  rheumatic  valve
isease  in  our  country  [3,13].
The  most  remarkable  ﬁnding  of  our  study  was  the  asso-
iation  of  RDW  with  outcome.  Survival  was  signiﬁcantly
ower  in  the  increased  RDW  group,  with  higher  in-hospital
nd  overall  mortality  rates.  In  the  Cox  proportional-hazards
nalysis,  elevated  RDW  on  admission  was  an  indicator  of  1-
ear  survival  before  and  after  adjusting  for  other  potential
onfounders.  In  addition  to  its  relationship  with  mortality,
omplications  of  IE  and  in-hospital  events  were  more  com-
on  in  subjects  with  elevated  RDW.  Our  results  suggest  that
DW  may  become  a  valuable  biomarker  for  estimating  poor
utcome  in  these  patients.  To  the  best  of  our  knowledge,
his  is  the  ﬁrst  study  that  has  evaluated  the  association  of
DW  with  mortality  in  IE.
RDW  is  a  recently  proposed  biomarker  of  adverse
utcomes.  Studies  have  reported  that  higher  RDW  is
n  independent  predictor  of  mortality  in  a  broad
pectrum  of  cardiovascular  diseases,  such  as  heart  fail-
re,  stable  coronary  disease,  acute  coronary  syndrome,
cute  pulmonary  embolism  and  pulmonary  hypertension
6,8,9,14,15].  Besides  mortality,  RDW  also  predicts  mor-
idity,  such  as  recurrent  hospital  admissions  or  recurrent
nfarctions  in  patients  with  acute  coronary  syndromes
15,16].
Although  information  regarding  the  role  of  RDW  in  IE
s  not  available  in  the  literature,  it  has  been  studied  in
ystemic  infections  and  inﬂammatory  diseases.  In  a  recent
tudy,  an  association  between  RDW  and  mortality  was
emonstrated  in  patients  with  severe  sepsis  and  septic
hock  [17].  In  another  study,  elevated  RDW  levels  were
elated  to  increased  short-term  mortality  in  patients  with
ram-negative  bacteraemia  [18]. Braun  et  al.  found  that
levated  RDW  predicted  longer  hospital  stay,  intensive  care
dmissions  and  90-day  mortality  in  young  patients  with
ommunity-acquired  pneumonia  [19].  In  a  study  by  Hu  et  al.,
DW  was  correlated  with  disease  activity  in  systemic  lupus
rythematosus,  a  chronic  disease  that  resembles  IE,  with
mmune  complexes  and  active  inﬂammatory  status  [20].
imilar  results  were  observed  in  a  study  of  inﬂammatory
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Table  3  Univariate  and  multivariable  Cox  proportional-hazards  analysis  of  1-year  survival.
Variables  Univariate  analysis  Multivariable  analysis
HR  (95%  CI)  P  HR  (95%  CI)  P
Age  1.01 0.99—1.03 0.16
Female  sex  0.66  0.34—1.27  0.21
Nosocomial  infection  1.77  0.78—4.01  0.16
Previous  IE  1.32  0.52—3.38  0.55
Prosthetic  valve  1.37  0.74—2.54  0.30
Pre-existing  valvular  disease  1.75  0.92—3.31  0.08
Multiple  valve  involvement  1.24  0.44—3.48  0.68
Dehiscence  2.65  1.03—6.77  0.04
Valvular  destruction  0.94  0.29—3.04  0.91
Severe  valvular  regurgitation 2.26 1.22—4.20 0.009
Vegetation  ≥  10  mm  1.31  0.68—2.5  0.40
Pulmonary  artery  pressure  1.02  0.99—1.04  0.05
Cardiac  abscess  3.59  1.49—8.63  0.004
Infection  with  Staphylococcus  aureus  1.31  0.62—2.76  0.46
Infection  with  Streptococci  0.37  0.11—1.22  0.10
Infection  with  Brucella  0.44  0.10—1.86  0.27
Infection  with  Enterecocci  2.51  0.98—6.45  0.08
RDW  >  15.3%  5.63  2.2—14.38  0.0001  3.07  1.06—8.86  0.03
Creatinine  1.42  1.13—1.78  0.003
Haemoglobin  0.87  0.75—1 0.06
Glucose  1  0.99—1 0.68
White  blood  cell  count  1.02  0.98—1.07  0.23
C-reactive  protein  1  0.99—1 0.40
Heart  failure  5.41  2.85—10.24  0.0001  2.77  1.1—6.97  0.03
Renal  failure  4.26  2.22—8.17  0.0001  3.21  1.35—7.59  0.008
Cerebrovascular  events  1.06  0.47—2.39  0.88
Embolic  event  (excluding  cerebral)  0.18  0.02—1.32  0.09
Anaemia  1.3  0.66—2.56  0.43
Surgery  for  IE 0.17 0.04—0.73  0.01
CI: conﬁdence interval; HR: hazard ratio; IE: infective endocarditis; RDW: red cell distribution width.
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tbowel  disease  [21].  According  to  our  ﬁndings,  C-reactive
protein  was  increased  in  patients  with  elevated  RDW,  sug-
gesting  that  inﬂammatory  status  was  more  aggravated  in
these  patients.  In  a  study  of  3845  outpatients,  RDW  had  a
strong  relationship  with  C-reactive  protein,  independent  of
confounding  factors  [22].The  mechanism  of  the  association  between  increased
RDW  and  poor  outcome  is  unclear.  RDW  reﬂects  the  presence
of  immature  and  larger  red  blood  cells  in  the  circulation  and
can  rise  in  any  condition  when  erythrocytes  are  destructed
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ar  produced  ineffectively.  Elevation  of  RDW  in  IE  may  be  a
esult  of  overt  inﬂammation.  The  release  of  cytokines  (such
s  tumour  necrosis  factor-  or  interleukin-6)  in  response
o  inﬂammation  decreases  the  half-life  of  red  blood  cells
hat  consequently  induce  accelerated  erythrocyte  produc-
ion  [23,24].  These  cytokines  can  desensitize  bone  marrow
rythroid  precursors  to  erythropoietin  by  blocking  its  matu-
ation  effects  and  cause  ineffective  erythropoiesis  [25—27].
ther  possible  mechanisms  are  increased  oxidative  stress
nd  lower  antioxidant  production,  which,  in  turn,  increase
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he  fragility  of  red  blood  cells,  decrease  the  rate  of  ery-
hroid  precursor  maturation  and  reduce  erythrocyte  lifespan
28—30].  In  various  studies,  RDW  predicted  mortality  bet-
er  than  haemoglobin  concentrations  [6,8,9,14—16]. Effects
f  inﬂammation  and  oxidative  stress  on  erythropoiesis  by
he  potential  mechanisms  mentioned  above  could  explain
hese  observations.  We  can  speculate  that  RDW  may  indi-
ate  underlying  co-morbidities  in  the  light  of  previous  work
ith  RDW  [6—9,14—22].
IE  has  a  broad-ranging  disease  course,  and  biomarkers
ay  facilitate  risk  stratiﬁcation  at  early  stages  in  this  com-
lex  disease.  C-reactive  protein  was  not  found  to  be  useful
n  identifying  worse  outcome  according  to  our  ﬁndings,
lthough  it  was  elevated  in  fatal  cases.  Unlike  our  results,
revious  studies  have  suggested  that  C-reactive  protein  is  a
redictor  of  mortality  in  IE  [5,31].  The  main  difference  in  our
tudy  was  the  longer  follow-up  period.  We  can  hypothesize
hat  C-reactive  protein  may  predict  short-term  outcome,
hereas  RDW  may  be  more  successful  for  long-term  pre-
iction  due  to  its  possible  ability  to  identify  underlying
o-morbidities.  Studies  have  also  demonstrated  that  ele-
ated  troponin,  B-type  natriuretic  peptide  and  procalcitonin
oncentrations  are  associated  with  morbidity  and  mortality
n  IE  [32—35].  None  of  these  studies  evaluated  long-term
ortality  and  most  enrolled  a  limited  number  of  study  sub-
ects.  Although  these  biomarkers  may  be  valuable  in  some
ases,  routine  follow-up  would  be  expensive  compared  with
DW.
Success  in  prediction  of  adverse  outcome,  availability
rom  the  complete  blood  count  and  lack  of  expense  make
DW  a  promising  biomarker  for  routine  clinical  practice.  The
xact  cut-off  value  of  RDW  for  identifying  high-risk  patients
iffers  in  the  literature:  in  some  papers,  the  median  value  of
he  study  cohorts  was  selected;  in  others,  ROC  curves  were
sed  for  optimum  cut-off  levels.  According  to  our  ﬁndings
nd  in  the  light  of  the  data  in  the  literature  so  far,  RDW
pproximately  above  15%  is  the  threshold  to  pay  attention
o  [9,16].  Elevated  RDW  levels  should  alert  clinicians  to  take
ore  aggressive  measures  in  order  to  prevent  poor  outcome.
tudy limitations
he  main  limitations  of  the  present  study  were  retrospec-
ive  design  and  small  sample  size.  Referral  bias  may  have
ffected  our  clinical  data,  as  the  participating  institutions
ere  both  tertiary  care  centres.  Being  a  referral  centre
ight  also  have  resulted  in  more  culture  negative  results  due
o  possible  antibiotic  use  prior  to  hospital  admission.  Due  to
etrospective  data-gathering  limitations,  we  could  not  ana-
yse  the  data  on  transfusion  status  or  nutritional  deﬁciencies
efore  admission,  which  may  have  affected  RDW  results.
atients  with  end-stage  renal  disease  were  not  excluded.
owever,  after  adjusting  RDW  for  haemoglobin  and  creati-
ine  concentrations  by  multivariable  analysis,  a  signiﬁcant
ssociation  remained  between  RDW  and  mortality.
Despite  the  higher  prevalence  of  prosthetic  valve  IE,
urgery  and  abscess  rates  were  lower  compared  with
revious  data.  Due  to  local  restrictions  and  retrospective
imitations  we  could  only  gather  data  from  the  study  insti-
utions.  We  evaluated  only  the  index  hospitalization  period
nd  did  not  further  follow  outcome  (such  as  surgery  after
ischarge,  reinfection  or  relapse)  apart  from  mortality.Y.  Guray  et  al.
urthermore,  the  cardiac  rhythm  devices  were  extracted
ith  percutaneous  procedures  and  were  not  grouped  under
he  title  of  surgery.
Our  study  population  was  different  from  those  in  Western
ountries;  the  patients  were  younger  and  prosthetic  valves
ere  more  common.  Therefore,  RDW  should  also  be  tested
n  other  populations.  The  speciﬁcity  of  RDW  in  detecting
ortality  was  lower,  limiting  the  role  of  RDW  in  exclusion.
iven  the  higher  number  of  tested  variables  compared  with
he  number  of  events,  we  could  not  exclude  the  risk  of
hance  ﬁnding.  We  did  not  evaluate  the  prognostic  value
f  RDW  in  a  ﬁrst  cohort  and  validate  it  in  another  cohort,
hich  would  have  improved  the  methodology  of  the  paper.
uture  prospective  studies  are  needed  to  conﬁrm  our  ﬁnd-
ngs,  with  larger  patient  cohorts  to  overcome  the  limitations
isted  above.
onclusion
ur  results  suggest  that  IE  has  a  high  mortality  rate  and  that
ncreased  RDW  is  an  independent  predictor  of  mortality  in
hese  patients.  The  use  of  RDW  as  a  prognostic  marker  may
rovide  valuable  information  for  early  risk  stratiﬁcation  in
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